Our lab studies the glycobiology of human diseases and works towards the development of new therapeutics.
We have adopted an interdisciplinary approach to disease research, from cell biology to protein expression and chemical synthesis. Our research is bolstered by close collaborations with leading scientists in the institute, across Australia and abroad.
We provide an excellent interdisciplinary training environment for students and postdoctoral researchers alike. Modern molecular biology and chemical biology techniques are used to study and prosecute novel disease targets.
Typical lab activities involve:
Australia, The University of Western Australia, BSc (Hons), PhD
2022 TIA Pipeline Accelerator
2021 NHMRC Project Grant – GNT2000517 (CIA)
2021 CTxONE pipeline accelerator
2021 TIA Pipeline Accelerator
2021 CFA Cystic Fibrosis Lung Health Grant
2021 Geok Hua Wong Charitable Trust Equipment Grant
2019 Brian M Davis Centenary Fellowship
2017 NHMRC Project Grant – GNT1139546 (CIA)
2017 NHMRC Project Grant – GNT1139549 (CIA)
2016 Speedy Innovation Award
2013 VESKI Innovation Fellowship
2013 Perpetual Ramaciotti Establishment Award
Lopaticki S, McConville R, John A, Geoghegan N, Mohamed SD, Verzier L, et al. Goddard-Borger ED*, Boddey JA*. Tryptophan C-mannosylation is critical for Plasmodium falciparum transmission. Nat Commun. 2022;13(1):4400. PMID: 35906227
Sharma M, Lingford JP, Petricevic M, Snow AJD, Zhang Y, Järvå MA, Mui JW-Y, Scott NE, Saunders EC, Mao R, Epa R, da Silva BM, Pires DEV, Ascher DB, McConville MJ, Davies GJ*, Williams SJ*, Goddard-Borger ED*. Oxidative desulfurization pathway for complete catabolism of sulfoquinovose by bacteria. Proc Natl Acad Sci U S A. 2022;119(4), e2116022119. PMID: 35074914
John A, Järvå MA, Shah S, Mao R, Chappaz S, Birkinshaw RW, Czabotar PE, Lo AW, Scott NE, Goddard-Borger ED*. Yeast- and antibody-based tools for studying tryptophan C-mannosylation. Nat Chem Biol. 2021;17(4):428-37. PMID: 3354253
Mao R, Xi S, Shah S, Roy MJ, John A, Lingford JP, Gäde G, Scott NE, Goddard-Borger ED*. Synthesis of C-Mannosylated Glycopeptides Enabled by Ni-Catalyzed Photoreductive Cross-Coupling Reactions. J Am Chem Soc. 2021;143(32):12699-707. PMID: 34346681
Järvå MA, Lingford JP, John A, Soler NM, Scott NE, Goddard-Borger ED*. Trefoil factors share a lectin activity that defines their role in mucus. Nat Commun. 2020;11(1):2265. PMID: 32404934
Järvå MA, Dramicanin M, Lingford JP, Mao R, John A, Jarman KE, Grinter R, Goddard-Borger ED*. Structural basis of substrate recognition and catalysis by fucosyltransferase 8. J Biol Chem. 2020;295(19):6677-88. PMID: 32220931.
Khurana S, Coffey MJ, John A, Uboldi AD, Huynh MH, Stewart RJ, Carruthers VB, Tonkin CJ*, Goddard-Borger ED*, Scott NE*. Protein O-fucosyltransferase 2-mediated O-glycosylation of the adhesin MIC2 is dispensable for Toxoplasma gondii tachyzoite infection. J Biol Chem. 2019;294(5):1541-53. PMID: 30514763.
Abayakoon P, Jin Y, Lingford JP, Petricevic M, John A, Ryan E, Mui JW-Y, Pires DV, Ascher DB, Davies GJ*, Goddard-Borger ED*, Williams SJ*. Structural and Biochemical Insights into the Function and Evolution of Sulfoquinovosidases. ACS Cent Sci. 2018;4(9):1266-73. PMID: 30276262
Lopaticki S, Yang ASP, John A, Scott NE, Lingford JP, O’Neill MT, Erickson SM, McKenzie NC, Jennison C, Whitehead LW, Douglas DN, Kneteman NM, Goddard-Borger ED, Boddey JA. Protein O-fucosylation in Plasmodium falciparum ensures efficient infection of mosquito and vertebrate hosts. Nat Commun. 2017, 8(1):561. PMID: 28916755
Speciale G, Jin Y, Davies GJ, Williams SJ, Goddard-Borger ED. YihQ is a sulfoquinovosidase that cleaves sulfoquinovosyl diacylglyceride sulfolipids. Nat Chem Biol. 2016 Apr;12(4):215-7 PMID: 26878550
Malaria remains one of the most significant problems in human health and represents a tremendous burden on the world’s poorest nations. The malaria parasites, and other apicomplexan parasites, rely on gliding motility to migrate through biological tissues and invade or emerge from host cells.
We have recently discovered that a key component of the molecular machinery involved in gliding motility is modified with an unusual glycan that, in higher eukaryotes, is essential for correct protein trafficking.
We are characterising this glycosylation pathway in collaboration with the Boddey laboratory at the institute, and developing chemical compounds that target it.
Asthma, cystic fibrosis and COPDs are characterised by the overproduction of mucus, which restricts the airways and makes it difficult for patients to breathe. Thinning this mucus to aid in its clearance, without completely ablating this protective coating of the epithelium, remains a challenging problem in the clinic.
Mucin proteins, the principle component of mucus, form complex polymeric networks to impart mucus with it high viscosity. Disrupting these intermolecular interactions is an effective means of thinning mucus.
We are collaborating with the Allan laboratory at the institute to develop a range of proteins that disrupt mucin-mucin interactions to treat diseases of the airways.
Inflammatory bowel diseases (IBDs) affect around 1 per cent of the population in the western world. Changes in the microbiota of these patients play a key role in disease progression with a notable loss of the colonic bacteria that produce short chain fatty acids (SCFAs). Microbial SCFAs nourish colonocytes, reduce epithelial barrier leakage, prime the innate immune response and potentiate the differentiation of regulatory T cells to keep autoimmune responses in check.
This project has been identifying polysaccharides in our diet that promote the growth of SCFA-producing bacteria. These could be used as supplements to aid in the management of IBDs.